CTLA4 and cancer: The introduction of immune checkpoint inhibitors, such as anti-CTLA-4 (ipilimumab) [29] and anti-PD-1 (nivolumab, pembrolizumab), has demonstrated significant clinical success in treating various cancers, including melanoma, lung cancer, and renal cell carcinoma [30].